Ionis Pharmaceuticals, Inc. (IONS): Price and Financial Metrics

Ionis Pharmaceuticals, Inc. (IONS): $42.03

0.52 (-1.22%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add IONS to Watchlist
Sign Up

IONS Price/Volume Stats

Current price $42.03 52-week high $54.44
Prev. close $42.55 52-week low $32.87
Day low $41.97 Volume 968,300
Day high $42.78 Avg. volume 1,247,436
50-day MA $48.10 Dividend yield N/A
200-day MA $45.21 Market Cap 6.13B

IONS Stock Price Chart Interactive Chart >

IONS POWR Grades

  • Quality is the dimension where IONS ranks best; there it ranks ahead of 62.24% of US stocks.
  • The strongest trend for IONS is in Growth, which has been heading down over the past 26 weeks.
  • IONS ranks lowest in Momentum; there it ranks in the 6th percentile.

IONS Stock Summary

  • Of note is the ratio of IONIS PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; only 6.43% of US stocks have a lower such ratio.
  • With a price/sales ratio of 12.03, IONIS PHARMACEUTICALS INC has a higher such ratio than 91% of stocks in our set.
  • Over the past twelve months, IONS has reported earnings growth of -1,682.44%, putting it ahead of merely 0.97% of US stocks in our set.
  • Stocks that are quantitatively similar to IONS, based on their financial statements, market capitalization, and price volatility, are XNCR, VIR, ATRA, SYRS, and ARVN.
  • IONS's SEC filings can be seen here. And to visit IONIS PHARMACEUTICALS INC's official web site, go to www.ionispharma.com.

IONS Valuation Summary

  • IONS's price/earnings ratio is -17.7; this is 160.72% lower than that of the median Healthcare stock.
  • Over the past 243 months, IONS's price/sales ratio has gone up 5.

Below are key valuation metrics over time for IONS.

Stock Date P/S P/B P/E EV/EBIT
IONS 2023-12-29 11.8 23.0 -17.7 -26.6
IONS 2023-12-28 11.8 23.0 -17.7 -26.5
IONS 2023-12-27 11.7 22.8 -17.6 -26.4
IONS 2023-12-26 12.0 23.3 -18.0 -26.9
IONS 2023-12-22 11.9 23.3 -17.9 -26.8
IONS 2023-12-21 11.5 22.3 -17.2 -25.9

IONS Growth Metrics

    Its 2 year price growth rate is now at -29.96%.
  • Its year over year price growth rate is now at -0.78%.
  • Its 3 year cash and equivalents growth rate is now at 44.36%.
IONS's revenue has moved down $371,386,000 over the prior 34 months.

The table below shows IONS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 587.367 -274.37 -269.722
2022-09-30 875.483 129.512 7.321
2022-06-30 848.809 98.367 -28.153
2022-03-31 840.768 53.811 -3.893
2021-12-31 810.456 30.799 -28.597
2021-09-30 660.731 -74.911 -593.481

IONS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IONS has a Quality Grade of C, ranking ahead of 48.06% of graded US stocks.
  • IONS's asset turnover comes in at 0.277 -- ranking 161st of 682 Pharmaceutical Products stocks.
  • EDIT, MYMD, and VSTM are the stocks whose asset turnover ratios are most correlated with IONS.

The table below shows IONS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.277 0.982 -0.099
2021-06-30 0.269 0.983 -0.073
2021-03-31 0.262 0.983 -0.051
2020-12-31 0.250 0.984 -0.031
2020-09-30 0.298 0.990 0.050
2020-06-30 0.306 0.992 0.063

IONS Price Target

For more insight on analysts targets of IONS, see our IONS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.82 Average Broker Recommendation 1.82 (Hold)

Ionis Pharmaceuticals, Inc. (IONS) Company Bio


Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.


IONS Latest News Stream


Event/Time News Detail
Loading, please wait...

IONS Latest Social Stream


Loading social stream, please wait...

View Full IONS Social Stream

Latest IONS News From Around the Web

Below are the latest news stories about IONIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IONS as an investment opportunity.

3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies

These future trillion dollar stocks can solidify portfolio growth for long-term investors.

William Cao on InvestorPlace | December 28, 2023

Ionis Pharmaceuticals Inc EVP, Chief Scientific Officer C Bennett Sells 22,613 Shares

Ionis Pharmaceuticals Inc (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, has experienced a recent insider sell according to a SEC Filing.

Yahoo | December 24, 2023

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.

Yahoo | December 21, 2023

CORRECTED-UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug

The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug, branded as Wainua, is approved for patients with polyneuropathy, or nerve damage caused by hereditary transthyretin amyloidosis (ATTR-PN), which affects an estimated 40,000 patients globally. Transthyretin amyloidosis is a progressive condition characterized by the build-up of abnormal protein deposits in the body's organs and tissues.

Yahoo | December 21, 2023

12 Most Promising Gene Editing Stocks According to Hedge Funds

In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can take a look at the 5 Most Promising […]

Yahoo | December 20, 2023

Read More 'IONS' Stories Here

IONS Price Returns

1-mo -5.40%
3-mo -13.04%
6-mo -1.06%
1-year 18.06%
3-year -22.47%
5-year -47.79%
YTD -16.92%
2023 33.94%
2022 24.12%
2021 -46.18%
2020 -6.41%
2019 11.75%

Continue Researching IONS

Want to see what other sources are saying about Ionis Pharmaceuticals Inc's financials and stock price? Try the links below:

Ionis Pharmaceuticals Inc (IONS) Stock Price | Nasdaq
Ionis Pharmaceuticals Inc (IONS) Stock Quote, History and News - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!